Last Update 07 Apr 26

NAGE: Core Strength And Injectables Will Support Future Upside Potential

Analysts have trimmed their price target on Niagen Bioscience to $13 from $14, citing updated models after Q4 results that reflect steady demand in the core business and possible upside from the injectable segment.

Analyst Commentary

Analysts see the updated price target as largely reflecting model clean up after Q4, rather than a shift in the overall view on the business. The focus now is on how consistently Niagen Bioscience can execute in its core operations while building out the injectable opportunity.

Bullish Takeaways

Bullish analysts highlight that the price target change to $13 from $14 still embeds confidence in the core business, which they view as providing a foundation for valuation support.
Steady demand in the core segment is seen as helping to underpin revenue visibility, which can reduce earnings volatility in their models.
Potential upside from the injectable business is viewed as an additional growth driver that, if executed well, could justify higher earnings assumptions over time.
Keeping a positive stance on the shares signals that, even after revising assumptions, analysts still see room for value creation if the company delivers against expectations.

Bearish Takeaways

Bearish analysts point to the trimmed target as a sign that prior expectations may have been too optimistic, prompting more conservative assumptions in their models.
The injectable business is treated as a source of potential upside, but there is caution around timing and execution, which may limit how much value is included in current forecasts.
Steady, rather than accelerating, demand in the core business leads some analysts to temper expectations for near term growth in revenue and earnings.
The lower target price suggests some concern that the previous valuation left limited room for error if the company underperforms internal plans.

What's in the News

Niagen Bioscience engaged OneSpaWorld as a Niagen Plus provider, offering pharmaceutical grade Niagen IV at over 80 Medi-Spa clinics on high end cruise ships, extending access to more than 1,200 healthcare, wellness, and longevity clinics across the U.S. (Client Announcements)
Niagen IV (500 mg) is now available through Wells Pharma of Houston, a U.S. FDA registered outsourcing facility, as a premium onboard OneSpaWorld service, with rollout tailored to individual ship Medi-Spa operations and regulatory requirements. (Client Announcements)
The company announced the Niagen Skincare Innovation Lab and its first product, Niagen NanoCloud, a limited release topical skincare sachet featuring the Niagen ingredient and a blend of hyaluronic acid, pullulan, squalane, and vitamin E, priced at US$59 for 30 sachets on truniagen.com. (Product Related Announcements)
A consumer perception study cited by the company found that consistent use of Niagen NanoCloud is associated with smoother, more hydrated, youthful looking skin, with visible results starting in as few as 2 weeks. (Product Related Announcements)
Niagen Bioscience partnered with Truemed so qualified customers can use HSA and FSA funds to purchase Tru Niagen on the company’s direct to consumer website with a Letter of Medical Necessity, adding more payment flexibility for buyers of its NAD+ supplement. (Client Announcements)

Valuation Changes

Fair Value: Model fair value is unchanged at $13.6, indicating no revision to the core valuation output.
Discount Rate: The discount rate has risen slightly from 7.07% to 7.21%, reflecting a modestly higher required return in the updated model.
Revenue Growth: The forecast revenue growth assumption is broadly stable, moving from 18.14% to 18.15% in the latest update.
Net Profit Margin: The net profit margin assumption has eased from 19.78% to 19.14%, implying a slightly more conservative view on future profitability.
Future P/E: The future P/E multiple has risen slightly from 33.21x to 34.45x, suggesting a higher valuation multiple applied to projected earnings.

10 views

Key Takeaways

Expansion into pharmaceutical-grade Niagen and increased e-commerce performance could drive revenue growth through direct-to-consumer channels and enhanced demand.
Increased R&D investments and legal settlements might strengthen the balance sheet and lead to potential high-margin pharmaceutical developments.
Intense competition, regulatory challenges, and rising expenses could pressure ChromaDex's revenue and margins amidst unresolved supply chain and legal issues.

Catalysts

About ChromaDex

Operates as a bioscience company focusing on developing healthy aging products.What are the underlying business or industry changes driving this perspective?

Expansion into the pharmaceutical-grade Niagen ingredient market, including the launch of Niagen IV and injections at clinics, is expected to drive future revenue growth due to increasing demand and the anticipated resolution of supply chain issues.
Continued e-commerce growth, supported by a significant increase in the Shopify platform's performance and a rising awareness of NAD-boosting products, suggests potential for further revenue growth and improved net margins due to the higher profitability of direct-to-consumer channels.
Planned increases in R&D investments, alongside a potential investigational drug application for the use of NR in the treatment of ataxia telangiectasia, could lead to future earnings growth if successful pharmaceutical developments result in new, high-margin products.
The resolution of reversals of royalty obligations and recoveries from legal settlements contribute to a stronger balance sheet, potentially allowing for reinvestment in growth initiatives and enhancing future net income stability.
The planned company rebranding and name change, aligned with strategic direction, may boost investor interest and market positioning, potentially impacting future revenue by attracting new consumer awareness and business development opportunities.

ChromaDex Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Niagen Bioscience's revenue will grow by 18.2% annually over the next 3 years.
Analysts assume that profit margins will increase from 13.4% today to 19.1% in 3 years time.
Analysts expect earnings to reach $40.9 million (and earnings per share of $0.49) by about April 2029, up from $17.4 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 34.6x on those 2029 earnings, up from 20.6x today. This future PE is greater than the current PE for the US Personal Products industry at 20.6x.
Analysts expect the number of shares outstanding to grow by 1.66% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.21%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Significant competition from companies entering the NAD booster market using practices such as patent infringement, false labeling, and poor manufacturing, which could negatively impact ChromaDex's revenue through increased market dilution.
Supply chain issues, particularly with the pharmaceutical-grade Niagen and the Niagen IV injections, have caused delays and might affect revenue and operational efficiency if not fully resolved.
Dependence on regulatory approvals poses a risk, as any adverse outcome in regulatory reviews or clinical trials (e.g., with the FDA) could hinder product availability and future sales, impacting earnings.
Legal issues, such as the ongoing lawsuit regarding NMN regulations, could impact ChromaDex's products if regulatory outcomes do not favor the company's current strategies, potentially affecting revenue streams.
Increased selling and marketing expenses anticipated in 2025 could pressure net margins if revenue growth does not meet expectations, particularly in the face of intense market competition.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $13.6 for Niagen Bioscience based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $18.0, and the most bearish reporting a price target of just $12.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $213.5 million, earnings will come to $40.9 million, and it would be trading on a PE ratio of 34.6x, assuming you use a discount rate of 7.2%.
Given the current share price of $4.47, the analyst price target of $13.6 is 67.1% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Niagen Bioscience?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Niagen IV Launch And E-commerce Growth Will Strengthen Future Prospects